
## Anne-Marie Mes-Masson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5505492/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer. Oncogene, 2022, 41, 309-320.	5.9	4
2	Signaling by the tyrosine kinase Yes promotes liver cancer development. Science Signaling, 2022, 15, eabj4743.	3.6	7
3	The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 715-727.	2.5	0
4	Plasma Gelsolin Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of Macrophage Subtypes. Cancers, 2022, 14, 1039.	3.7	11
5	Pre-activation of autophagy impacts response to olaparib in prostate cancer cells. Communications Biology, 2022, 5, 251.	4.4	6
6	Spatially mapping the immune landscape of melanoma using imaging mass cytometry. Science Immunology, 2022, 7, eabi5072.	11.9	60
7	Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability. Molecular Cancer Therapeutics, 2022, 21, 407-418.	4.1	2
8	High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific Mortality. Cancers, 2022, 14, 1623.	3.7	5
9	Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants. Genes, 2022, 13, 697.	2.4	3
10	The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population. Cancers, 2022, 14, 2251.	3.7	4
11	Targeting a Tumor-Specific Epitope on Podocalyxin Increases Survival in Human Tumor Preclinical Models. Frontiers in Oncology, 2022, 12, .	2.8	6
12	High Levels of MFG-E8 Confer a Good Prognosis in Prostate and Renal Cancer Patients. Cancers, 2022, 14, 2790.	3.7	3
13	Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers. Journal of Ovarian Research, 2022, 15, .	3.0	4
14	Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression. Npj Precision Oncology, 2022, 6, .	5.4	9
15	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology, 2021, 34, 194-206.	5.5	21
16	Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. Gynecologic Oncology, 2021, 160, 568-578.	1.4	21
17	Genomic analysis of lowâ€grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. Journal of Pathology, 2021, 253, 41-54.	4.5	54
18	Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines. Cancers, 2021, 13, 1296.	3.7	3

#	Article	IF	CITATIONS
19	High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer. , 2021, 9, e001965.		16
20	SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. International Journal of Gynecological Pathology, 2021, 40, 487-494.	1.4	7
21	Elevated Expression of Glycerol-3-Phosphate Phosphatase as a Biomarker of Poor Prognosis and Aggressive Prostate Cancer. Cancers, 2021, 13, 1273.	3.7	4
22	Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and Mortality. Cancers, 2021, 13, 1688.	3.7	5
23	Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	12
24	A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis. International Journal of Molecular Sciences, 2021, 22, 5325.	4.1	16
25	The Biobanque québécoise de la COVID-19 (BQC19)—A cohort to prospectively study the clinical and biological determinants of COVID-19 clinical trajectories. PLoS ONE, 2021, 16, e0245031.	2.5	30
26	Nuclear HKII–P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer. Cancers, 2021, 13, 3399.	3.7	5
27	Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families. Npj Breast Cancer, 2021, 7, 109.	5.2	3
28	Microdissected Tissue vs Tissue Slices—A Comparative Study of Tumor Explant Models Cultured On-Chip and Off-Chip. Cancers, 2021, 13, 4208.	3.7	13
29	Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models. Scientific Reports, 2021, 11, 18183.	3.3	22
30	A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. Genome Medicine, 2021, 13, 186.	8.2	12
31	The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance. Oncogene, 2020, 39, 1600-1616.	5.9	85
32	Distinct Histologic, Immunohistochemical and Clinical Features Associated With Serous Endometrial Intraepithelial Carcinoma Involving Polyps. International Journal of Gynecological Pathology, 2020, 39, 128-135.	1.4	5
33	Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. Gynecologic Oncology, 2020, 156, 377-386.	1.4	14
34	Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer. Cancers, 2020, 12, 3339.	3.7	15
35	Comparing Perspectives of Canadian Men Diagnosed With Prostate Cancer and Health Care Professionals About Active Surveillance. Journal of Patient Experience, 2020, 7, 1122-1129.	0.9	3
36	Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease. Cancers, 2020, 12, 2222.	3.7	10

#	Article	IF	CITATIONS
37	PUMA and NOXA Expression in Tumor-Associated Benign Prostatic Epithelial Cells Are Predictive of Prostate Cancer Biochemical Recurrence. Cancers, 2020, 12, 3187.	3.7	4
38	Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa. Modern Pathology, 2020, 33, 2361-2377.	5.5	4
39	Ran GTPase: A Key Player in Tumor Progression and Metastasis. Frontiers in Cell and Developmental Biology, 2020, 8, 345.	3.7	59
40	Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN). Journal of the National Cancer Institute, 2020, 112, 1098-1104.	6.3	21
41	Plasma Gelsolin Inhibits CD8+ T-cell Function and Regulates Glutathione Production to Confer Chemoresistance in Ovarian Cancer. Cancer Research, 2020, 80, 3959-3971.	0.9	28
42	Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls. Scientific Reports, 2020, 10, 6491.	3.3	24
43	Comparison and Analysis of Two Internationally Recognized Biobanking Standards. Biopreservation and Biobanking, 2020, 18, 82-89.	1.0	8
44	Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems. PLoS ONE, 2020, 15, e0244549.	2.5	16
45	Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas. Current Drug Targets, 2020, 21, 974-995.	2.1	3
46	Canadian Tissue Repository Network Biobank Certification Program: Update and Review of the Program from 2011 to 2018. Biopreservation and Biobanking, 2019, 17, 530-538.	1.0	8
47	Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. PLoS Medicine, 2019, 16, e1002847.	8.4	23
48	Exome Sequencing in BRCA1- and BRCA2-Negative Greek Families Identifies MDM1 and NBEAL1 as Candidate Risk Genes for Hereditary Breast Cancer. Frontiers in Genetics, 2019, 10, 1005.	2.3	15
49	The molecular origin and taxonomy of mucinous ovarian carcinoma. Nature Communications, 2019, 10, 3935.	12.8	110
50	Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer. Scientific Reports, 2019, 9, 13924.	3.3	16
51	Paraffin-embedding lithography and micro-dissected tissue micro-arrays: tools for biological and pharmacological analysis of <i>ex vivo</i> solid tumors. Lab on A Chip, 2019, 19, 693-705.	6.0	14
52	CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis. American Journal of Pathology, 2019, 189, 1451-1461.	3.8	9
53	Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion. Nature Communications, 2019, 10, 2666.	12.8	35
54	Long-term fluorescence hyperspectral imaging of on-chip treated co-culture tumour spheroids to follow clonal evolution. Integrative Biology (United Kingdom), 2019, 11, 130-141.	1.3	4

#	Article	IF	CITATIONS
55	Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nature Communications, 2019, 10, 2556.	12.8	132
56	A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma. Journal of Pathology: Clinical Research, 2019, 5, 177-188.	3.0	11
57	A Review of International Biobanks and Networks: Success Factors and Key Benchmarks—A 10-Year Retrospective Review. Biopreservation and Biobanking, 2019, 17, 512-519.	1.0	10
58	Prognostic value of progesterone receptor expression in tuboâ€ovarian highâ€grade serous carcinoma of the <scp>COEUR</scp> cohort. Histopathology, 2019, 74, 663-666.	2.9	3
59	A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores. Pathology and Oncology Research, 2019, 25, 979-986.	1.9	4
60	V-ATPase-associated prorenin receptor is upregulated in prostate cancer after PTEN loss. Oncotarget, 2019, 10, 4923-4936.	1.8	12
61	The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancerâ€specific survival. Prostate, 2018, 78, 697-706.	2.3	25
62	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. BMC Cancer, 2018, 18, 347.	2.6	67
63	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. BMC Urology, 2018, 18, 78.	1.4	14
64	Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer. Cancers, 2018, 10, 379.	3.7	21
65	Replication Protein A Availability during DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells. Cancer Research, 2018, 78, 5561-5573.	0.9	45
66	Fluorescence hyperspectral imaging for live monitoring of multiple spheroids in microfluidic chips. Analyst, The, 2018, 143, 3829-3840.	3.5	16
67	Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion. Breast Cancer Research, 2018, 20, 9.	5.0	23
68	Hormonal and reproductive factors and the risk of ovarian cancer. Cancer Causes and Control, 2017, 28, 393-403.	1.8	30
69	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nature Genetics, 2017, 49, 856-865.	21.4	220
70	Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers. Scientific Reports, 2017, 7, 13244.	3.3	24
71	Morphologic three-dimensional scanning of fallopian tubes to assist ovarian cancer diagnosis. Journal of Biomedical Optics, 2017, 22, 076012.	2.6	11
72	Functionally Null <i>RAD51D</i> Missense Mutation Associates Strongly with Ovarian Carcinoma. Cancer Research, 2017, 77, 4517-4529.	0.9	34

#	Article	IF	CITATIONS
73	Microcystic, elongated, and fragmented pattern invasion is mainly associated with isolated tumor cell pattern metastases in International Federation of Gynecology and Obstetrics grade I endometrioid endometrial cancer. Human Pathology, 2017, 62, 33-39.	2.0	18
74	Biopsy Based Proteomic Assay Predicts Risk of Biochemical Recurrence after Radical Prostatectomy. Journal of Urology, 2017, 197, 1034-1040.	0.4	10
75	Analysis of active surveillance uptake for low-risk localized prostate cancer in Canada: a Canadian multi-institutional study. World Journal of Urology, 2017, 35, 595-603.	2.2	17
76	Canadian Men's perspectives about active surveillance in prostate cancer: need for guidance and resources. BMC Urology, 2017, 17, 98.	1.4	7
77	Dimension reduction technique using a multilayered descriptor for high-precision classification of ovarian cancer tissue using optical coherence tomography: a feasibility study. Journal of Medical Imaging, 2017, 4, 1.	1.5	9
78	Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines. Oncotarget, 2017, 8, 40152-40168.	1.8	25
79	ll̂ºB-Kinase-epsilon (ΙΚΚĴμ) over-expression promotes the growth of prostate cancer through the C/EBP-Ĵ² dependent activation of IL-6 gene expression. Oncotarget, 2017, 8, 14487-14501.	1.8	16
80	The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin. Scientific Reports, 2016, 6, 20508.	3.3	40
81	STAT1â€associated intratumoural T <sub>H</sub> 1 immunity predicts chemotherapy resistance in highâ€grade serous ovarian cancer. Journal of Pathology: Clinical Research, 2016, 2, 259-270.	3.0	42
82	Robust high-performance nanoliter-volume single-cell multiple displacement amplification on planar substrates. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8484-8489.	7.1	45
83	Optimized p53 immunohistochemistry is an accurate predictor of <i>TP53</i> mutation in ovarian carcinoma. Journal of Pathology: Clinical Research, 2016, 2, 247-258.	3.0	280
84	Morphologic 3D scanning of fallopian tubes to assist ovarian cancer diagnosis. , 2016, , .		2
85	Abstract LB-324: Genomic consequences of aberrant DNA repair stratify ovarian cancer histotypes. , 2016, , .		1
86	Abstract 448: Expression of Galectins in high grade serous ovarian cancer. , 2016, , .		0
87	Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors. BMC Medicine, 2015, 13, 217.	5.5	17
88	Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population. Oncology Letters, 2015, 9, 2787-2790.	1.8	7
89	Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. Breast Cancer Research, 2015, 17, 45.	5.0	103
90	PRP4K is a HER2-regulated modifier of taxane sensitivity. Cell Cycle, 2015, 14, 1059-1069.	2.6	22

#	Article	IF	CITATIONS
91	Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome. BMC Cancer, 2015, 15, 135.	2.6	19
92	A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population. Journal of Ovarian Research, 2015, 8, 1.	3.0	37
93	The Molecular Taxonomy of Primary Prostate Cancer. Cell, 2015, 163, 1011-1025.	28.9	2,435
94	Germline TP53 mutational spectrum in French Canadians with breast cancer. BMC Medical Genetics, 2015, 16, 24.	2.1	20
95	CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer. Cancer Research, 2015, 75, 4494-4503.	0.9	186
96	Potential Cross-Talk between Alternative and Classical NF-κB Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay. PLoS ONE, 2015, 10, e0131024.	2.5	18
97	Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease. Genes and Cancer, 2015, 6, 378-398.	1.9	28
98	RAN Nucleo-Cytoplasmic Transport and Mitotic Spindle Assembly Partners XPO7 and TPX2 Are New Prognostic Biomarkers in Serous Epithelial Ovarian Cancer. PLoS ONE, 2014, 9, e91000.	2.5	37
99	A Framework for Biobank Sustainability. Biopreservation and Biobanking, 2014, 12, 60-68.	1.0	105
100	A Practical Tool for Modeling Biospecimen User Fees. Biopreservation and Biobanking, 2014, 12, 234-239.	1.0	15
101	The RelB alternative NF-kappaB subunit promotes autophagy in 22Rv1 prostate cancer cells in vitro and affects mouse xenograft tumor growth in vivo. Cancer Cell International, 2014, 14, 67.	4.1	6
102	Tissue Microarrays in Studying Gynecological Cancers. , 2014, , 65-76.		3
103	Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer. European Journal of Cancer, 2013, 49, 2441-2448.	2.8	40
104	Specimen Quality Evaluation in Canadian Biobanks Participating in the COEUR Repository. Biopreservation and Biobanking, 2013, 11, 83-93.	1.0	35
105	<i>VGLL3</i> expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer. Molecular Oncology, 2013, 7, 513-530.	4.6	41
106	Analysis of genomic abnormalities in tumors: a review of available methods for Illumina two-color SNP genotyping and evaluation of performance. Cancer Genetics, 2013, 206, 103-115.	0.4	9
107	Contribution of the PALB2 c.2323C>T [p.Q775X] Founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent. BMC Medical Genetics, 2013, 14, 5.	2.1	25
108	Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression. Gynecologic Oncology, 2013, 128, 356-363.	1.4	50

#	Article	IF	CITATIONS
109	Gata3 antagonizes cancer progression in Pten-deficient prostates. Human Molecular Genetics, 2013, 22, 2400-2410.	2.9	37
110	Empirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform. Biomicrofluidics, 2013, 7, 11805.	2.4	44
111	Generating a Comprehensive Set of Standard Operating Procedures for a Biorepository Network—The CTRNet Experience. Biopreservation and Biobanking, 2013, 11, 387-396.	1.0	19
112	Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes and Development, 2013, 27, 900-915.	5.9	158
113	Positional Mapping and Candidate Gene Analysis of the Mouse Ccs3 Locus That Regulates Differential Susceptibility to Carcinogen-Induced Colorectal Cancer. PLoS ONE, 2013, 8, e58733.	2.5	5
114	FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome. International Journal of Oncology, 2013, 42, 912-920.	3.3	29
115	Establishment of Primary Cultures from Ovarian Tumor Tissue and Ascites Fluid. Methods in Molecular Biology, 2013, 1049, 323-336.	0.9	21
116	PTP1B Is an Androgen Receptor–Regulated Phosphatase That Promotes the Progression of Prostate Cancer. Cancer Research, 2012, 72, 1529-1537.	0.9	74
117	p53 Inhibits Angiogenesis by Inducing the Production of Arresten. Cancer Research, 2012, 72, 1270-1279.	0.9	58
118	Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i> / <i>2</i> French Canadian Founder Mutation. Cancer Prevention Research, 2012, 5, 765-777.	1.5	0
119	Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer. International Journal of Oncology, 2012, 40, 1865-80.	3.3	19
120	Combination of Serum Biomarkers to Differentiate Malignant From Benign Ovarian Tumours. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 567-574.	0.7	14
121	Certification for Biobanks: The Program Developed by the Canadian Tumour Repository Network (CTRNet). Biopreservation and Biobanking, 2012, 10, 426-432.	1.0	45
122	Necdin modulates proliferative cell survival of human cells in response to radiation-induced genotoxic stress. BMC Cancer, 2012, 12, 234.	2.6	7
123	Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC Cancer, 2012, 12, 379.	2.6	59
124	Necdin, a p53-Target Gene, Is an Inhibitor of p53-Mediated Growth Arrest. PLoS ONE, 2012, 7, e31916.	2.5	11
125	BTN3A2 Expression in Epithelial Ovarian Cancer Is Associated with Higher Tumor Infiltrating T Cells and a Better Prognosis. PLoS ONE, 2012, 7, e38541.	2.5	84
126	ErbB2/Herâ€2 regulates the expression of Akt2 in prostate cancer cells. Prostate, 2012, 72, 777-788.	2.3	6

#	Article	IF	CITATIONS
127	The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent. Breast Cancer Research and Treatment, 2012, 131, 333-340.	2.5	16
128	Stimulation of Wnt/ß-Catenin Pathway in Human CD8+ T Lymphocytes from Blood and Lung Tumors Leads to a Shared Young/Memory Phenotype. PLoS ONE, 2012, 7, e41074.	2.5	25
129	The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome. PLoS ONE, 2012, 7, e45484.	2.5	41
130	NF-κB p65 as a prognostic tool in prostate cancer: An immunohistochemical study from biopsy samples Journal of Clinical Oncology, 2012, 30, e15202-e15202.	1.6	0
131	H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic geneBCL2determines ERα ligand dependency. EMBO Journal, 2011, 30, 3947-3961.	7.8	77
132	Influence of pH on the cytotoxic activity of inositol hexakisphosphate (IP6) in prostate cancer. Frontiers in Oncology, 2011, 1, 40.	2.8	1
133	Subtype Specific Elevated Expression of Hyaluronidase-1 (HYAL-1) in Epithelial Ovarian Cancer. PLoS ONE, 2011, 6, e20705.	2.5	26
134	Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours. PLoS ONE, 2011, 6, e28250.	2.5	82
135	KIF1A, an Axonal Transporter of Synaptic Vesicles, Is Mutated in Hereditary Sensory and Autonomic Neuropathy Type 2. American Journal of Human Genetics, 2011, 89, 219-230.	6.2	172
136	Subtypeâ€specific mutation of <i>PPP2R1A</i> in endometrial and ovarian carcinomas. Journal of Pathology, 2011, 223, 567-573.	4.5	114
137	lκBâ€Kinaseâ€îμ (IKKε/IKKi/IκBKε) expression and localization in prostate cancer tissues. Prostate, 2011, 71, 113	31213138.	18
138	Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells. Molecular Carcinogenesis, 2011, 50, 901-912.	2.7	22
139	Impact of hemochromatosis gene ( <i>HFE</i> ) mutations on epithelial ovarian cancer risk and prognosis. International Journal of Cancer, 2011, 128, 2326-2334.	5.1	27
140	Regulation of E2Fs and senescence by PML nuclear bodies. Genes and Development, 2011, 25, 41-50.	5.9	132
141	Role of Pirh2 in Mediating the Regulation of p53 and c-Myc. PLoS Genetics, 2011, 7, e1002360.	3.5	65
142	Protease inhibitor SERPINA1 expression in epithelial ovarian cancer. Clinical and Experimental Metastasis, 2010, 27, 55-69.	3.3	35
143	Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer. Familial Cancer, 2010, 9, 507-517.	1.9	22
144	Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. Journal of Pathology, 2010, 220, 392-400.	4.5	92

#	Article	IF	CITATIONS
145	Strong cytotoxic effect of the bradykinin antagonist BKMâ€570 in ovarian cancer cells – analysis of the molecular mechanisms of its antiproliferative action. FEBS Journal, 2010, 277, 5146-5160.	4.7	25
146	A novel method of cell embedding for tissue microarrays. Histopathology, 2010, 57, 323-329.	2.9	6
147	Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies. Cancers, 2010, 2, 913-954.	3.7	25
148	Effect of Ovarian Cancer Ascites on Cell Migration and Gene Expression in an Epithelial Ovarian Cancer In Vitro Model. Translational Oncology, 2010, 3, 230-238.	3.7	33
149	An essential role for Ran GTPase in epithelial ovarian cancer cell survival. Molecular Cancer, 2010, 9, 272.	19.2	59
150	<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas. New England Journal of Medicine, 2010, 363, 1532-1543.	27.0	1,460
151	Androgen-Regulated Expression of Arginase 1, Arginase 2 and Interleukin-8 in Human Prostate Cancer. PLoS ONE, 2010, 5, e12107.	2.5	45
152	Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. Journal of Immunological Methods, 2009, 348, 9-17.	1.4	219
153	Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer. Molecular Carcinogenesis, 2009, 48, 648-661.	2.7	17
154	Characterization of the 3p12.3â€p <i>cen</i> region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. Molecular Carcinogenesis, 2009, 48, 1077-1092.	2.7	34
155	Overâ€expression of lκBâ€kinaseâ€îµ (IKKε/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines. Prostate, 2009, 69, 706-718.	2.3	34
156	BMP-2 signaling in ovarian cancer and its association with poor prognosis. Journal of Ovarian Research, 2009, 2, 4.	3.0	66
157	The chemiluminescence based Ziplex® automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip® expression profiles. Journal of Translational Medicine, 2009, 7, 55.	4.4	8
158	Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary. New England Journal of Medicine, 2009, 360, 2719-2729.	27.0	706
159	Molecular Genetic Analysis of a Cell Adhesion Molecule With Homology to L1CAM, Contactin 6, and Contactin 4 Candidate Chromosome 3p26pter Tumor Suppressor Genes in Ovarian Cancer. International Journal of Gynecological Cancer, 2009, 19, 513-525.	2.5	18
160	Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast Cancer Research and Treatment, 2008, 108, 399-408.	2.5	33
161	Ebp1 expression in benign and malignant prostate. Cancer Cell International, 2008, 8, 18.	4.1	13
162	Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines. BMC Medical Genomics, 2008, 1, 34.	1.5	23

#	Article	IF	CITATIONS
163	Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Molecular Carcinogenesis, 2008, 47, 56-65.	2.7	24
164	Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. BJU International, 2008, 101, 1302-1309.	2.5	22
165	Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics, 2008, 9, 99.	2.8	93
166	Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer, 2008, 8, 152.	2.6	48
167	Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. BMC Cancer, 2008, 8, 346.	2.6	11
168	Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer, 2008, 8, 96.	2.6	21
169	BTF4/BTNA3.2 and GCS as Candidate mRNA Prognostic Markers in Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 913-920.	2.5	15
170	Regulation of lκB Kinase ε Expression by the Androgen Receptor and the Nuclear Factor-κB Transcription Factor in Prostate Cancer. Molecular Cancer Research, 2007, 5, 87-94.	3.4	23
171	Improvement of Antitumor Activity by Gene Amplification with a Replicating but Nondisseminating Adenovirus. Cancer Research, 2007, 67, 3387-3395.	0.9	19
172	NOXA and PUMA Expression Add to Clinical Markers in Predicting Biochemical Recurrence of Prostate Cancer Patients in a Survival Tree Model. Clinical Cancer Research, 2007, 13, 7044-7052.	7.0	32
173	Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. International Journal of Oncology, 2007, , .	3.3	20
174	Characterization of Ovarian Cancer Ascites on Cell Invasion, Proliferation, Spheroid Formation, Gene Expression in an In Vitro Model of Epithelial Ovarian Cancer. Neoplasia, 2007, 9, 820-IN8.	5.3	131
175	Comparative proteome analysis of human epithelial ovarian cancer. Proteome Science, 2007, 5, 16.	1.7	47
176	An apoptotic molecular network identified by microarray: On the TRAIL to new insights in epithelial ovarian cancer. Cancer, 2007, 110, 297-308.	4.1	18
177	Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Molecular Carcinogenesis, 2007, 46, 872-885.	2.7	217
178	Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. BJU International, 2007, 100, 303-309.	2.5	31
179	NF-κB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells. Cellular Signalling, 2007, 19, 1093-1100.	3.6	27
180	A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families. Familial Cancer, 2007, 6, 491-497.	1.9	25

#	Article	IF	CITATIONS
181	Haplotype analysis suggest common founders in carriers of the recurrent BRCA2mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. BMC Medical Genetics, 2006, 7, 23.	2.1	20
182	An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines. Prostate, 2006, 66, 1245-1256.	2.3	17
183	Presence of prostate cancer metastasis correlates with lower lymph node reactivity. Prostate, 2006, 66, 1710-1720.	2.3	28
184	From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. International Journal of Cancer, 2006, 118, 1750-1758.	5.1	49
185	Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. International Journal of Cancer, 2006, 119, 599-607.	5.1	121
186	SET complex in serous epithelial ovarian cancer. International Journal of Cancer, 2006, 119, 2119-2126.	5.1	55
187	Nuclear Localization of Nuclear Factor-κB p65 in Primary Prostate Tumors Is Highly Predictive of Pelvic Lymph Node Metastases. Clinical Cancer Research, 2006, 12, 5741-5745.	7.0	75
188	Expression and Nuclear Localization of ErbB3 in Prostate Cancer. Clinical Cancer Research, 2006, 12, 2730-2737.	7.0	114
189	Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene, 2005, 24, 4672-4687.	5.9	72
190	Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. Molecular Carcinogenesis, 2005, 43, 141-154.	2.7	46
191	Proteome profiling of human epithelial ovarian cancer cell line TOV-112D. Molecular and Cellular Biochemistry, 2005, 275, 25-55.	3.1	35
192	EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate, 2005, 65, 130-140.	2.3	61
193	Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells. Prostate, 2005, 65, 306-315.	2.3	30
194	OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer. International Journal of Oncology, 2005, 27, 1315.	3.3	7
195	Identification of novel variant, 1484delC in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors. International Journal of Oncology, 2005, 26, 1621-7.	3.3	2
196	Signature of a silent killer: expression profiling in epithelial ovarian cancer. Expert Review of Molecular Diagnostics, 2004, 4, 157-167.	3.1	29
197	Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGF?-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemotherapy and Pharmacology, 2004, 54, 497-504.	2.3	46
198	Expression of NFâ€₽̂B in prostate cancer lymph node metastases. Prostate, 2004, 58, 308-313.	2.3	88

#	Article	IF	CITATIONS
199	Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5BRCA1 andBRCA2 mutations. International Journal of Cancer, 2004, 112, 411-419.	5.1	41
200	Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogenously staining region. Molecular Carcinogenesis, 2004, 41, 17-38.	2.7	21
201	Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene, 2003, 22, 1568-1579.	5.9	32
202	Expression Profiles of 290 ESTs Mapped to Chromosome 3 in Human Epithelial Ovarian Cancer Cell Lines Using DNA Expression Oligonucleotide Microarrays. Genome Research, 2002, 12, 112-121.	5.5	17
203	Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci andTP53 mutations in human epithelial ovarian cancer. Molecular Carcinogenesis, 2002, 34, 78-90.	2.7	24
204	Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene, 2001, 20, 6617-6626.	5.9	70
205	Haplotype Analysis of <i>BRCA2</i> 8765delAG Mutation Carriers in French Canadian and Yemenite Jewish Hereditary Breast Cancer Families. Human Heredity, 2001, 52, 116-120.	0.8	27
206	Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. Oncogene, 2000, 19, 1466-1472.	5.9	22
207	Trisomy of Chromosome 10 in Two Cases of Ovarian Carcinoma. Cancer Genetics and Cytogenetics, 2000, 118, 65-68.	1.0	3
208	Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clinical Genetics, 1999, 55, 318-324.	2.0	55
209	Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites. , 1999, 24, 218-225.		12
210	The humanTDE gene homologue: Localization to 20q13.1-13.3 and variable expression in human tumor cell lines and tissue. Molecular Carcinogenesis, 1999, 26, 189-200.	2.7	17
211	Mapping of chromosome 3p deletions in human epithelial ovarian tumors. Oncogene, 1998, 17, 2359-2365.	5.9	38
212	Risk factors for familial and sporadic ovarian cancer among French Canadians: A case-control study. American Journal of Obstetrics and Gynecology, 1998, 179, 403-410.	1.3	61
213	Founder BRCA1 and BRCA2 Mutations in French Canadian Breast and Ovarian Cancer Families. American Journal of Human Genetics, 1998, 63, 1341-1351.	6.2	156
214	Discordance in p53 Mutations When Comparing Ascites and Solid Tumors from Patients with Serous Ovarian Cancer. Tumor Biology, 1997, 18, 167-174.	1.8	11
215	Polyomavirus large T-antigen binds the â€~pRb related' protein p130 through sequences in conserved region 2. Virus Research, 1997, 47, 85-90.	2.2	9
216	Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Letters, 1996, 99, 185-189.	7.2	56

#	Article	IF	CITATIONS
217	Polyomavirus large T antigen zinc finger is not required for efficient cellular immortalization of primary rat embryo fibroblasts. Virus Research, 1996, 46, 171-175.	2.2	1
218	Sequence analysis of a novel cDNA which is overexpressed in testicular tumors from polyomavirus large T-antigen transgenic mice. DNA Sequence, 1994, 5, 31-39.	0.7	17
219	Establishment and Characterization of Testicular Cell Lines from MT-PVLT-10 Transgenic Mice. Experimental Cell Research, 1994, 213, 12-19.	2.6	16
220	Sequence analysis of the large and small subunits of human ribonucleotide reductase. DNA Sequence, 1992, 2, 227-234.	0.7	32
221	Testicular adenoma and seminal vesicle engorgement in polyomavirus large-T antigen transgenic mice. Molecular Carcinogenesis, 1992, 5, 178-189.	2.7	10
222	Role of the abl Oncogene in Chronic Myelogenous Leukemia. Advances in Cancer Research, 1987, 49, 53-74.	5.0	11
223	Microfluidics and spectroscopic imaging for personalized medicine in ovarian cancer. SPIE Newsroom, 0,	0.1	1